Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03874052
Title Ruxolitinib in Combination With Venetoclax for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute

acute myeloid leukemia


Ruxolitinib + Venetoclax

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.